Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News RXi Pharmaceuticals Corp RXII

Healthcare Biotechnology
"RXi Pharmaceuticals Corp is a clinical-stage RNAi company developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which address significant unmet medical needs."

Recent & Breaking News (NDAQ:RXII)

RXi Pharmaceuticals to Present New Data in its First Phase 2a Clinical Trial with RXI-109

PR Newswire October 7, 2014

RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum

PR Newswire September 29, 2014

RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference

PR Newswire September 18, 2014

RXi Pharmaceuticals Strengthens Intellectual Property Portfolio

PR Newswire September 17, 2014

RXi Pharmaceuticals Presented an Update on the Company's Dermatology and Ophthalmology Franchises

PR Newswire September 11, 2014

RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

PR Newswire September 3, 2014

RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014

PR Newswire August 14, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

RXi Pharmaceutical Corporation (NASDAQ: RXII) to Ring The NASDAQ Stock Market Closing Bell

GlobeNewswire August 7, 2014

RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell

PR Newswire August 4, 2014

RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars

PR Newswire July 30, 2014

What RXi Pharmaceuticals' Move to the Russell Microcap Index Means

Accesswire July 9, 2014

RXi Pharmaceuticals Appoints Peter Campochiaro M.D. to its Scientific Advisory Board

PR Newswire July 7, 2014

RXi Pharmaceuticals Celebrates Expansion of its Operations in Massachusetts

PR Newswire July 2, 2014

RXi Pharmaceuticals Set to Join Russell Microcap Index

PR Newswire June 25, 2014

RXi Pharma Advances sd-rxRNA Platform with Key Patent

Accesswire June 9, 2014

RXi Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference

PR Newswire May 27, 2014

RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform

PR Newswire May 22, 2014

RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2014

PR Newswire May 14, 2014

RXi Pharmaceuticals Announces Positive Results with RXI?109 in the Eyes of Cynomolgus Monkeys as Part of a Dose Range Finding Study

PR Newswire May 2, 2014